A venture capital firm based in the USA is interested in a broad range of technology companies, including those in the software, cloud services, IT, and Internet sectors. In the life sciences, the firm will only invest in the healthcare IT sector. The firm invests in late seed to early Series A rounds with a typical investment size ranges from $1M-$5M. Investment is typically in form of equity, though convertible notes would be considered as well. The firm will look at investment opportunities across the US West Coast and in Texas.

The firm will make new investments in the digital health sector. The firm is interested in healthcare services and IT companies targeting platform, enterprise software, m-health, solution, data analytics and consumer health. The firm will invest in commercial-stage companies with products or services on the market.

The firm invests in privately held healthcare companies. The firm focuses on companies with annual revenues of between $0.5M and $10M.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

An investment firm headquartered in Europe, with additional offices in USA and Asia seeks to invest in innovations directly related to the prevention of age-associated diseases, extension of a healthy lifespan, and improving the performance of humans and animals. The firm’s initial check size can range from $500K – 1.5M, and the firm is open to global opportunities.

Within life sciences, the firm is most interested in therapeutics and diagnostics companies, and will also consider digital health. Medical devices with traditional regulatory pathways are generally out of scope for the firm. Within these sectors, interest areas can include gene therapy, telomere attrition, proteostasis, regenerative medicine, personalized diagnostics/biomarkers, preventative therapies, cognitive enhancement, and more. That said, the firm has no strong interest in particular technologies and is open to all modalities. The firm is also opportunistic in terms of stage of development.

The firm seeks companies with strong, protectable IP with clear origins and ownership, backed by a diverse team with a strong track record and technologies with validated proof of concept. The firm has a 3-step due diligence process which includes: (1) initial review, (2) additional review – where the firm looks more closely into main differentiating factors of the company (IP, business model, etc.), and (3) final review. The firm is open to leading, co-leading, or co-investing, and has a strong co-investment and syndication network of likeminded investors.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A private investment firm was founded in 1965 and is based in California, USA. The firm invests in seed and early-stage digital health and therapeutic companies. The typical investment size for seed investment ranges from $500K to $1M (usually in equity or capped, convertible notes). For early-stage companies, the firm typically co-invests with other VC firms in Seed and Series A financing and the investment size will depend on the company’s financial needs. The firm is geographically agnostic but prefers start-ups to be based in the United States. The firm is actively seeking new investment opportunities.

The firm is actively seeking new investment opportunities in the digital health sector and areas of interest include: Precision medicine, digital therapeutics, combination data products, scalability solutions and clinical trial management solutions.

The firm often leads financings and takes a board seat, but prefers to syndicate on opportunities.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

The firm is a venture capital firm that was founded in 2005 and it is based in Germany. The firm with about EUR 900 million under management currently invests out of its third fund. The firm focuses on investments in technology-based early stage companies in life science industry among other technologically oriented industries. The venture capitalist provides initial investments of up to EUR 600,000-1 million. The firm will also reserve a further EUR 3 million for follow-on financing and supports the start-ups in acquiring other investors and partners. The firm is interested in companies that have been in operation for less than one year. The firm typically targets 12-15 life science investments per year. The firm invests primarily in Germany but also has the capacity to invest in other parts of Europe with ties to Germany. For the first investment, startups should be less than 3 years old. 

The firm is looking for new opportunities in the life science space including therapeutics, diagnostics, medical devices, material sciences, chemicals, regenerative energies and healthcare IT sectors. The firm is opportunistic in terms of sector, subsectors and indications, but it focuses on companies with a significant technological innovation or business model and close to proof of concept. The firm’s investments to date have included life science companies developing medical devices, vaccines, drugs development, diagnostic services, chemicals and platform technologies. 

The firm only invests in seed-stage companies located in Germany (or at least with ties to Germany: money spend there). The founding team should have the relevant know-how, complimentary skills and relevant business / industry experience. Outside of Germany, the firm only invests as a co-investor alongside a local investor. 

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com. 

The firm is Canada’s leading healthcare VC Firm. Based in Toronto, the firm typically makes equity investments into digital health and AI enabled medical device companies at seed / series A-B stages and follow on rounds. The typical investment size ranges from $1.5 million to $ 7 million. The firm seeks to invest in approx. 2-5 digital health/AI enabled medical device companies per year and focuses on companies based in North America, Europe and the GCC region. 

The firm is currently looking for new investment opportunities in the Digital Health and AI enabled Medical Device spaces. The firm is opportunistic in terms of indications. The firm prefers to invest in non-invasive device companies with clinical validation and some in-human data with a clear path to clinical adoption & reimbursement. For Digital Health, the firm prefers to invest in companies developing data platforms aimed at improving outcomes or processes, with first market pilots complete and approx. $250k ARR. 

The firm seeks to invest in private companies. The firm considers pre-revenue companies, depending on sector and in companies who have has a strong commercial and technical management team. 

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com. 

The firm is an agetech-focused seed-stage VC firm, founded in 2016 and based in New York. The firm is focused on all aspects of agetech, whether helping older adults live at home longer, assisting caregivers or facilities in elder care. Within healthcare, the firm invests in companies such as digital health, digital therapeutics, and remote monitoring, among others. The firm currently invests in companies in North America, Europe and Israel, and will soon invest in Asia and the South Pacific as well. The firm generally invests $50-150K in companies that have demonstrated early signs of market traction, and may invest up to $300K over the lifetime of the investment. 

The firm will consider investments in any technology relating to agetech that does not require clinical trials. This can include companies developing technologies relating to remote monitoring, those assisting caregivers, digital therapeutics, among others. 

The firm generally co-invests. They can be as involved as the company requires, taking a more active role if they can be of assistance to the company in any way. 

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com. 

A venture capital firm founded in China with over $4 billion in total managed assets in the areas of healthcare, technology and internet, and cleantech has invested in more than 70 healthcare companies, that span most sectors of life sciences from pharmaceuticals and medical devices to healthcare IT, diagnostics and select healthcare services.

The firm’s US fund is focused on early-stage health care opportunities in the US with potential market opportunities in China, and the USA team is spread out across multiple locations across the country. The firm intends to lead, co-lead, or co-invest in US-based private companies in biotech for therapeutics, Medtech, and digital health technologies, with equity investments ranging from $5 to $20 million. The firm will not make public company investments.

The firm is open to many sectors in the life science space – biotech therapeutics, medical devices, diagnostics, and healthcare IT. The firm is most interested in breakthrough products and technologies that address a large unmet need. The firm seeks investments in 510K devices and will invest in devices in the PMA pathway depending on stage, preferably clinical or later. In therapeutics, the firm is modality-agnostic but generally seeking opportunities that are past the pre-clinical stage. The firm is also interested in enabling technologies for drug discovery and development, and other healthcare-related technologies in the “digital-health” space.

The firm is seeking to invest in companies with novel ideas and technology and experienced and passionate management. Given the firm’s slogan of “inspiring people with the wisdom to succeed with diligence,” The firm’s team is “hands-on” and typically assumes a board seat after an investment. In general, the firm invests globally and prefers companies that have upside opportunities in China and can leverage the firm’s China network and expertise.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.